When Taxol met tubulin [Classics]

When the drug Taxol® was approved by the United States Food and Drug Administration in 1993, it was a game changer for cancer patients. The compound, which arrests cell division by preventing the disassembly of tubulin microfibers, has been used over the past three decades to treat millions of cases of breast, lung, and ovarian cancer as well as Kaposi's sarcoma. In 1990, Bristol Myers Squibb applied to trademark the name Taxol, which was approved in 1992, changing the drug's generic name to paclitaxel.At the time that Taxol was entering clinical trials in the late 1970s, it also proved to be a valuable tool for cytoskeletal research. Tubulin had been discovered in the late 1960s, but it was still unclear how the soluble protein dimer polymerized (Fig. 1) to form the long, complex structures of the cytoskeleton.jbc;295/41/13994/F1F1F1Figure 1.Strands of tubulin, a protein in the cell's skeleton, photographed using a high-resolution microscopy technique. Image made by Pakorn Kanchanawong (National University of Singapore) and Clare Waterman (NHLBI, National Institutes of Health).“Back then, people were just discovering the most basic functions of tubulin and how it polymerized, and then they found a drug that affected this,” said Velia Fowler, a cell biologist at the University of Delaware and former Associate Editor at the Journal of Biological Chemistry.The drug and its cytoskeletal activity intersected in the 1981 JBC paper “Taxol-induced polymerization of purified t...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Classics Source Type: research